# Sindh Institute of Cardiovascular Diseases: Phase 3 study completed, 100 enrolled (Pulmonary Hypertension, Rheumatic Valvular Heart Disease)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Sindh Institute of Cardiovascular Diseases |
| Sponsor type | Academic and hospital |
| Study | Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT) |
| NCT ID | NCT07462260 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Pulmonary Hypertension; Rheumatic Valvular Heart Disease |
| Intervention types | drug |
| Target enrollment | 100 |
| Site countries | Pakistan |
| Posted | 2026-03-10 |
| Planned start | 2025-08-01 |
| Event | Completed |
| Event date | 2026-09-23 |
| Last update posted | 2026-09-24 |

## Why this score
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 100 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07462260). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.